Research interests
Diabetes, stem cells and epigenetics
Diabetes is a chronic metabolic disease in which a person has high blood sugar levels either because the body does not produce enough insulin (type1 diabetes), or because of insulin irresponsiveness (type2 diabetes). The loss of pancreatic beta cells causes insulin dependency in diabetes. While increased circulating insulin may promote pancreatic cancer. Regeneration of pancreatic beta-cell thus provides the next generation of diabetes treatment and elimination of its complications. In this study, the epigenetic modifications on the genome, as illustrated below, that lead to diabetic conditions were explored, to understand the disease etiology and develop possible diagnostic tools.
Epigenetic modifications that drive step-wise differentiation of stem cells to pancreatic beta cells were also explored to assist regenerative medicine technologies for diabetes. See publications.
Iron metabolism in anemia of chronic diseases - Hepcidin Diagnostic
Hepcidin, a hormone secreted by the liver, is a principal regulator of systemic iron homeostasis. It regulates body iron levels by inhibiting intestinal iron absorption and sequestering iron in the macrophages. Hepcidin inhibits cellular iron efflux by degrading ferroportin, the cellular iron exporter as illustrated in the figure below. In this study, hepcidin reduction leads to iron overload in hemochromatosis. Interestingly, hepcidin is elevated in many chronic conditions and contributed to the development of anemia of chronic diseases, possibly due to an evolutionary mechanism to limit iron availability to invading microorganisms. Here, the regulation of iron metabolism by hepcidin and molecular signaling of hepcidin in chronic conditions including chronic infections (e.g. malaria, shown below), chronic inflammation (e.g. obesity and diabetes) and malignancy/cancer were identified. See publications.
Atherosclerosis and inflammatory diseases - preclinical studies of iron chelators and supplements
Coronary heart disease and stroke have claimed the lives of millions of people each year. These diseases result from hypercholesterolemia, coupled with a chronic inflammatory condition of the vascular wall, termed atherosclerosis, that lead to vessel occlusion and various clinical manifestations. It is also commonly a result of diabetic and rheumatoid arthritis conditions. The study aimed to investigate the role of iron in the inflammatory events of atherogenesis, in the course of phagocyte-endothelial cell interactions in the artery, as shown in the video below. This study has revealed an immunomodulatory function of iron in inflammation. Non-transferrin bound iron promotes accumulation of intracellular labile iron and production of oxygen-derived free radicals, leading to cell activation. Activation of endothelial cells is a well-characterized phenotype that leads to endothelial dysfunction in vivo, which not only will initiate the development of atherosclerosis, but also plays a role in thrombosis, promoting vessel occlusion and acute cardiovascular events. In combination with chronic infections, iron enhances infection-induced endothelial activation and aggravates atherosclerosis. Iron alone promotes phagocyte activation and complicates the progression of atherosclerotic cardiovascular diseases. Furthermore, such infiltrating phagocytes are also involved in tumor progression to cancer by providing angiogenesis-associated activities, and neuroinflammation that stimulates development of neurodegenerative diseases.